Our studies demonstrated that cell lines derived from patients with MDS/AML or AML with erythroid features are generally less sensitive to gemtuzumab and PBD-conjugated ADCs targeting CD33 and CD123, compared to AML cell lines from patients with de novo or good- to intermediate-risk disease. The gene discussed is CD33; the disease is acute myeloid leukemia.